← Leaderboards
Alison B Edelman
Oregon Health & Science University
$5,115,754
Attributed
$6,993,817
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,993,817 · 8
By mechanism
R01$6,556,675 · 3
N01$174,689 · 1
P51$135,700 · 3
R03$126,753 · 1
Top collaborators
- Jon D Hennebold5 shared
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Alison Edelman$1,129,796
- Leo Liu Han$1,579,066
Others in their field
Top investigators on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$252,110,127
- Wafaa M. El-Sadr · Columbia University Health Sciences$232,152,340
- Myron S Cohen · Family Health International$208,921,087
- Barbara Driver · Westat, Inc.$190,429,693
- Judith S. Currier · University Of California Los Angeles$149,317,678
Research focus
WomanObesityOvulationProgesteroneContraceptive AgentsMonitorDoseDrug KineticsSerumPharmaceutical PreparationsEstradiolUnintended PregnancyBody Mass IndexBaseGrantEnrollmentDesignPregnancyContraceptive EfficacyHalf-LifeEstrogensReportingAnimalsOvary
Grant awards (20)
Pharmacogenomics of an ovulation modulator and the impact on delay of ovulation$787,879
R01 · FY2025 · HD · contact PI
NICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS (PK), PHARMACODYNAMIC (PD) EFFECTS, SAFETY, AND CONTRACEPTIVE EFFICACY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG-A$97,767
N01 · FY2025 · HD · contact PI
NICHD:R&D: OVAPRENE PHASE 1: PROTOCOL FINALIZATION, REGULATORY APPROVAL, START-UP, AND COMMENCEMENT OF RECRUITMENT, SCREENING, AND ENROLLMENT FOR THE OVAPRENE VAGINAL DEVICE CLINICAL TRIAL (NON-SEVER$70,441
N01 · FY2025 · HD · contact PI
NICHD:R&D:CENTRAL LABORATORY FOR A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION:NON-SEVERABLE$6,481
N01 · FY2025 · HD · contact PI
Disparities in emergency contraceptive metabolism dictate efficacy$1,061,388
R01 · FY2024 · HD · contact PI
Disparities in emergency contraceptive metabolism dictate efficacy$770,714
R01 · FY2023 · HD · contact PI
Disparities in emergency contraceptive metabolism dictate efficacy$336,431
R01 · FY2023 · HD · contact PI
Disparities in emergency contraceptive metabolism dictate efficacy$799,715
R01 · FY2022 · HD · contact PI
Determining the impact of COVID-19 vaccination on the menstrual cycle$296,124
R01 · FY2021 · HD · contact PI
Improving emergency contraceptive effectiveness in obese women$324,781
R01 · FY2020 · HD · contact PI
Improving emergency contraceptive effectiveness in obese women$333,114
R01 · FY2019 · HD · contact PI
Improving emergency contraceptive effectiveness in obese women$378,088
R01 · FY2018 · HD · contact PI
Improving emergency contraceptive effectiveness in obese women$369,055
R01 · FY2017 · HD · contact PI
Improving Contraceptive Effectiveness in Obese Women$460,240
R01 · FY2010 · HD · contact PI
DO ORAL CONTRACEPTIVES CAUSE WEIGHT GAIN?$47,603
P51 · FY2010 · RR · contact PI
Improving Contraceptive Effectiveness in Obese Women$639,146
R01 · FY2009 · HD · contact PI
DO ORAL CONTRACEPTIVES CAUSE WEIGHT GAIN?$60,393
P51 · FY2009 · RR · contact PI
DO ORAL CONTRACEPTIVES CAUSE WEIGHT GAIN?$27,704
P51 · FY2008 · RR · contact PI
Contraceptive efficacy and body weight: Does obesity affect the risk of failure?$60,066
R03 · FY2007 · HD · contact PI
Contraceptive efficacy and body weight: Does obesity affect the risk of failure?$66,687
R03 · FY2006 · HD · contact PI